AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26966825 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland's Central postero-anterior vertebral pressure for thoracic spine (T1-T8) in addition to individualized treatment for low back pain and home exercise program (HEP) of breathing exercises
Number of subjects: 62
Study 26966825 — intervention group
Group type: COMPARATOR
Intervention: Individualized treatment for low back pain and home exercise program (HEP) of breathing exercises
Number of subjects: 62
Study 24986816 — intervention group
Group type: EXPERIMENTAL
Intervention: A1 beta-casein milk (750 ml/day)
Number of subjects: 41
Study 24986816 — intervention group
Group type: COMPARATOR
Intervention: A2 beta-casein milk (750 ml/day)
Number of subjects: 41
Study 22488220 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral educational intervention
Number of subjects: 540
Study 22488220 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 540
Study 20855362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (2.5-45 mg)
Number of subjects: 130
Study 20855362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 20855362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (20 mg and higher)
Number of subjects: 130
Study 20855362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Number of subjects: 130
Study 17618954 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release metformin (SR)
Number of subjects: 55
Study 17618954 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-release metformin (RR)
Number of subjects: 55
Study 17618954 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 55
Study 15578245 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite mesh with hydrophilic resorbable film
Number of subjects: 80
Study 11023477 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (sargramostim) 125 microgram/m(2) subcutaneously twice weekly for 6 months
Number of subjects: 105
Study 11023477 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (sargramostim)
Number of subjects: 105
Study 9291767 — intervention group
Group type: COMPARATOR
Intervention: Nasal mask
Number of subjects: 50
Study 9291767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway
Number of subjects: 50
Study 8228207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 42‐5892 (600 mg orally, once a day)
Number of subjects: 8
Study 8228207 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg orally, once a day)
Number of subjects: 8
Study 3079482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0
Study 3079482 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2645889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene, 1.0 mg
Number of subjects: 0
Study 2645889 — intervention group
Group type: COMPARATOR
Intervention: Naloxone, 1.0 mg
Number of subjects: 0
Study 2645889 — intervention group
Group type: COMPARATOR
Intervention: Saline, 1.0 mL
Number of subjects: 0
Study 31894045 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride ointment
Number of subjects: 180
Study 31894045 — intervention group
Group type: COMPARATOR
Intervention: 10% iodine
Number of subjects: 180
Study 29050998 — intervention group
Group type: EXPERIMENTAL
Intervention: Detomidine (5 μg kg−1) with methadone (0.2 mg kg−1)
Number of subjects: 8
Study 29050998 — intervention group
Group type: COMPARATOR
Intervention: Saline (SAL)
Number of subjects: 8
Study 29050998 — intervention group
Group type: COMPARATOR
Intervention: Methadone (0.2 mg kg−1) alone (MET)
Number of subjects: 8
Study 29050998 — intervention group
Group type: COMPARATOR
Intervention: Detomidine (5 μg kg−1) alone (DET)
Number of subjects: 8
Study 29050998 — intervention group
Group type: EXPERIMENTAL
Intervention: Detomidine (2.5 μg kg−1) with methadone (0.2 mg kg−1) (MLD)
Number of subjects: 8
Study 29050998 — intervention group
Group type: EXPERIMENTAL
Intervention: Detomidine (5 μg kg−1) with methadone (0.2 mg kg−1) (MMD)
Number of subjects: 8
Study 29050998 — intervention group
Group type: EXPERIMENTAL
Intervention: Detomidine (10 μg kg−1) with methadone (0.2 mg kg−1) (MHD)
Number of subjects: 8
Study 25985940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held echocardiography (HHE)
Number of subjects: 100
Study 25985940 — intervention group
Group type: COMPARATOR
Intervention: Standard echocardiography
Number of subjects: 100
Study 24107879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptol, 1500 mg daily divided into three doses for 8 weeks
Number of subjects: 62
Study 21300344 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole at 1 mg/d
Number of subjects: 271
Study 21300344 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole at 5 mg/d
Number of subjects: 271
Study 21300344 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole at 10 mg/d
Number of subjects: 271
Study 21300344 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate at 50 mg/d
Number of subjects: 271
Study 20209968 — intervention group
Group type: EXPERIMENTAL
Intervention: Xianling Gubao capsules
Number of subjects: 110
Study 20209968 — intervention group
Group type: COMPARATOR
Intervention: Placebo of starch capsules
Number of subjects: 110
Study 17009251 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine estrogens (estrogen-alone trial)
Number of subjects: 26321
Study 17009251 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate (estrogen-plus-progestin trial)
Number of subjects: 26321
Study 17009251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both trials)
Number of subjects: 26321
Study 15504193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 70 microg kg(‐1) administered intravenously 3 min before induction of anaesthesia.
Number of subjects: 50
Study 15504193 — intervention group
Group type: COMPARATOR
Intervention: Saline administered intravenously 3 min before induction of anaesthesia (Control Group II).
Number of subjects: 50
Study 10940063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 96
Study 10940063 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision
Number of subjects: 96
Study 9497795 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemia (blood glucose 5 mmol/l)
Number of subjects: 0
Study 9497795 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hyperglycaemia (aimed at 15 mmol/l)
Number of subjects: 0
Study 9497795 — intervention group
Group type: COMPARATOR
Intervention: Intrajejunal fat administration (1 g/h) during normoglycaemia
Number of subjects: 0
Study 9497795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrajejunal fat administration (1 g/h) during hyperglycaemia
Number of subjects: 0
Study 9497795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat administration
Number of subjects: 0
Study 9497795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia
Number of subjects: 0
Study 7678184 — intervention group
Group type: EXPERIMENTAL
Intervention: TOAST classification system
Number of subjects: 20
Study 3745847 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose of liquid aluminum‐magnesium antacid (75 ml in five daily doses)
Number of subjects: 78
Study 3745847 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 78
Study 29847553 — intervention group
Group type: EXPERIMENTAL
Intervention: Local sugar sweetened beverage health promotion and 20p price increase
Number of subjects: 0
Study 27496239 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral feeding (liquid oral diet for 2 weeks with gradually expanding daily maximums)
Number of subjects: 148
Study 27496239 — intervention group
Group type: COMPARATOR
Intervention: Delayed oral feeding (enteral feeding via jejunostomy for 5 days followed by liquid oral diet)
Number of subjects: 148
Study 26016070 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (Toric‐IOL)
Number of subjects: 54
Study 26016070 — intervention group
Group type: COMPARATOR
Intervention: Peripheral corneal relaxing incisions (PCRIs)
Number of subjects: 54
Study 22541652 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (low-molecular-weight heparin) in intraocular infusion fluid (BSS)
Number of subjects: 20
Study 22541652 — intervention group
Group type: COMPARATOR
Intervention: No enoxaparin (control group)
Number of subjects: 20
Study 20228980 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide gel with carbopol as the thickening agent
Number of subjects: 45
Study 20228980 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carbopol gel
Number of subjects: 45
Study 20228980 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide paste with poloxamer as the thickening agent
Number of subjects: 45
Study 20228980 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer
Number of subjects: 45
Study 20228980 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide strips for 21 days
Number of subjects: 45
Study 18477382 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve sonography measurements in patients with severe brain injury (n=32)
Number of subjects: 76
Study 18477382 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve sonography measurements in patients with moderate brain injury (n=18)
Number of subjects: 76
Study 18477382 — intervention group
Group type: COMPARATOR
Intervention: Control individuals (n=26)
Number of subjects: 76
Study 18477382 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ONSD with estimated ICP in severe brain injury patients
Number of subjects: 76
Study 18477382 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ONSD with neuroimaging scale results in severe brain injury patients
Number of subjects: 76
Study 18477382 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ONSD with invasive ICP values in severe brain injury patients
Number of subjects: 76
Study 18477382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off value of ONSD for predicting elevated ICP in severe brain injury patients
Number of subjects: 76
Study 16025151 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care after ASCT
Number of subjects: 90
Study 16025151 — intervention group
Group type: COMPARATOR
Intervention: Control (hospital treatment)
Number of subjects: 90
Study 12535290 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased peritoneal clearance
Number of subjects: 0
Study 12535290 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard peritoneal clearance)
Number of subjects: 0
Study 10694766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofu diet (290 g/d)
Number of subjects: 42
Study 10694766 — intervention group
Group type: COMPARATOR
Intervention: Lean meat diet (150 g/d)
Number of subjects: 42
Study 9339181 — intervention group
Group type: EXPERIMENTAL
Intervention: OND+MPS (ondansetron 8 mg po before chemotherapy, methylprednisolone 120 mg IV before chemotherapy, followed by ondansetron 8 mg po and methylprednisolone 16 mg po on days 1-4)
Number of subjects: 364
Study 9339181 — intervention group
Group type: EXPERIMENTAL
Intervention: OND+MPS
Number of subjects: 364
Study 9339181 — intervention group
Group type: COMPARATOR
Intervention: TH (conventional antiemetic treatment: benzamide plus corticosteroids with or without benzodiazepines)
Number of subjects: 364
Study 9339181 — intervention group
Group type: COMPARATOR
Intervention: TH
Number of subjects: 364
Study 8368408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral postoperative corticosteroids
Number of subjects: 62
Study 8368408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sugar pill)
Number of subjects: 62
Study 8368408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (corticosteroids and placebo)
Number of subjects: 62
Study 3521858 — intervention group
Group type: EXPERIMENTAL
Intervention: imidazole.2-hydroxybenzoate
Number of subjects: 30
Study 3521858 — intervention group
Group type: COMPARATOR
Intervention: sulindac
Number of subjects: 30
Study 31801052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) as adjunctive therapy
Number of subjects: 81
Study 31067190 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring plus telemonitoring
Number of subjects: 0
Study 31067190 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring alone
Number of subjects: 0
Study 31067190 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27793960 — intervention group
Group type: EXPERIMENTAL
Intervention: cabozantinib 60 mg orally once daily
Number of subjects: 658
Study 27793960 — intervention group
Group type: COMPARATOR
Intervention: everolimus 10 mg orally once daily
Number of subjects: 658
Study 25287751 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist liraglutide (1.2 mg per day)
Number of subjects: 52
Study 23297810 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant cessation advice given to general practitioners in cases of overtreatment.
Number of subjects: 45
Study 23297810 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specific information given to general practitioners.
Number of subjects: 45
Study 23297810 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 45
Study 21654093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip strengthening prior to functional exercises
Number of subjects: 33
Study 21654093 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps strengthening prior to functional exercises
Number of subjects: 33
Study 21654093 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 18266551 — intervention group
Group type: EXPERIMENTAL
Intervention: alcohol + anxiety induction (n = 20)
Number of subjects: 80
Study 18266551 — intervention group
Group type: COMPARATOR
Intervention: placebo + anxiety induction (n = 20)
Number of subjects: 80
Study 18266551 — intervention group
Group type: EXPERIMENTAL
Intervention: alcohol + no anxiety induction (n = 20)
Number of subjects: 80
Study 18266551 — intervention group
Group type: COMPARATOR
Intervention: placebo + no anxiety induction (n = 20)
Number of subjects: 80
Study 17191734 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical conditioning at 25% Hmax
Number of subjects: 0
Study 17191734 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical conditioning at 50% Hmax
Number of subjects: 0
Study 17191734 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical conditioning at Hmax
Number of subjects: 0
Study 17191734 — intervention group
Group type: COMPARATOR
Intervention: Electrical conditioning at 25% Hmax
Number of subjects: 0
Study 17191734 — intervention group
Group type: COMPARATOR
Intervention: Electrical conditioning at 50% Hmax
Number of subjects: 0
Study 17191734 — intervention group
Group type: COMPARATOR
Intervention: Electrical conditioning at Hmax
Number of subjects: 0
Study 12709636 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 52
Study 12709636 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 10978397 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline group
Number of subjects: 829
Study 10978397 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 829
Study 8927668 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment with full doses of clomipramine, fluoxetine, or fluvoxamine
Number of subjects: 130
Study 8927668 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment with half doses of clomipramine, fluoxetine, or fluvoxamine
Number of subjects: 130
Study 8927668 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of pharmacotherapy
Number of subjects: 130
Study 8927668 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal from drug therapy (three subgroups)
Number of subjects: 130
Study 1839133 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional angioplasty
Number of subjects: 68
Study 1839133 — intervention group
Group type: COMPARATOR
Intervention: Laser thermal angioplasty
Number of subjects: 68
Study 6847173 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 300 mg/day
Number of subjects: 248
Study 6847173 — intervention group
Group type: COMPARATOR
Intervention: Rimantadine hydrochloride 300 mg/day
Number of subjects: 248
Study 6847173 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 200 mg/day
Number of subjects: 248
Study 6847173 — intervention group
Group type: COMPARATOR
Intervention: Rimantadine hydrochloride 200 mg/day
Number of subjects: 248
Study 6847173 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Number of subjects: 248
Study 6847173 — intervention group
Group type: COMPARATOR
Intervention: Rimantadine hydrochloride
Number of subjects: 248
Study 30871894 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physiotherapy (mobilization, ambulation, shoulder exercises, breathing exercises)
Number of subjects: 94
Study 30871894 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physiotherapy treatment)
Number of subjects: 94
Study 30311724 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% olive ointment (n = 37)
Number of subjects: 73
Study 30311724 — intervention group
Group type: COMPARATOR
Intervention: 1.5% calendula ointment (n = 39)
Number of subjects: 73
Study 26071866 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood grafts (PB)
Number of subjects: 494
Study 26071866 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonparticipants)
Number of subjects: 494
Study 26071866 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival, transplantation-related mortality, and incidences of acute or chronic graft-versus-host disease
Number of subjects: 494
Study 24350748 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led, asynchronous, online support group
Number of subjects: 0
Study 22307477 — intervention group
Group type: EXPERIMENTAL
Intervention: 750,000 IU/mo vitamin A supplementation
Number of subjects: 130
Study 22307477 — intervention group
Group type: COMPARATOR
Intervention: No supplemental vitamin A (unsupplemented)
Number of subjects: 130
Study 19614639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐AF group (30 patients)
Number of subjects: 90
Study 19614639 — intervention group
Group type: COMPARATOR
Intervention: No‐AF group (60 patients)
Number of subjects: 90
Study 17500048 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg metformin and 2.5 mg glibenclamide per coated tablet (intervention group)
Number of subjects: 0
Study 17500048 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15337557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy for ST‐PNETs
Number of subjects: 44
Study 12649946 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 I.U. for children > 12 months, 100,000 I.U. for children 6-12 months, 500,000 I.U. for children < 6 months) every 4 to 6 months for 15 months
Number of subjects: 1520
Study 12649946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1520
Study 9426014 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab bolus and infusion
Number of subjects: 2099
Study 9426014 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab bolus alone
Number of subjects: 2099
Study 9426014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099
Study 8752612 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily for 6 months)
Number of subjects: 25
Study 2331204 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 0
Study 2331204 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 2331204 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback/Protocol
Number of subjects: 0
Study 6932866 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 33
Study 6932866 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 33
Study 31248841 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (30-120 mg daily; mean 92.1 mg/day)
Number of subjects: 66
Study 31248841 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50-100 mg daily; mean 93.6 mg/day)
Number of subjects: 66
Study 27510947 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention
Number of subjects: 6
Study 27510947 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention (effectiveness design)
Number of subjects: 6
Study 27510947 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention (efficacy design)
Number of subjects: 6
Study 27510947 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention (overall efficacy)
Number of subjects: 6
Study 27510947 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention (pre-consent centres)
Number of subjects: 6
Study 27510947 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention (post-consent centres)
Number of subjects: 6
Study 26407981 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis intervention (two antenatal training sessions and a supporting CD)
Number of subjects: 343
Study 26407981 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis intervention
Number of subjects: 343
Study 24033696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 709
Study 24033696 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 709
Study 22190133 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU vitamin D3
Number of subjects: 22
Study 22190133 — intervention group
Group type: EXPERIMENTAL
Intervention: 150,000 IU vitamin D3
Number of subjects: 22
Study 22190133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20234305 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 20
Study 20234305 — intervention group
Group type: COMPARATOR
Intervention: Interactive seminar
Number of subjects: 20
Study 17573445 — intervention group
Group type: EXPERIMENTAL
Intervention: Papworth method (5 sessions)
Number of subjects: 85
Study 17573445 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 85